Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: A feasibility study

被引:0
|
作者
Coley, HM
Sargent, JM [1 ]
Williamson, CJ
Titley, J
Scheper, RJ
Gregson, SE
Elgie, AW
Lewandowicz, GM
Taylor, CG
机构
[1] Pembury Hosp, Pembury TN2 4QJ, Kent, England
[2] Inst Canc Res, CRC, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England
[3] Free Univ Amsterdam Hosp, Dept Pathol, NL-1007 MB Amsterdam, Netherlands
关键词
MDR; ovarian cancer; P-glycoprotein; chemosensitivity; drug modulation;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This in vitro feasibility study has assessed a number of techniques and their applicability when looking at the role of multidrug resistance (MDR) in solid tumours. Fresh tumour material was obtained from 34 patients, (11 previously treated, 23 untreated) with ovarian adenocarcinoma. Doxorubicin sensitivity was measured using the MTT assay +/- the cyclosporins, Pgp expression was assessed by immunocytochemistry with the MRK-16 MoAb and flow cytometry was used to assess intracellular drug accumulation +/- PSC 833. 85% of samples showed some evidence of modest chemosensitisation by the cyclosporins (median 1.74-fold). We saw a marked variation in the number of Pgp positive cells between patients (1-87%, median 31%). 63% of samples tested showed an enhancement of DNR accumulation in the presence of PSC 833, with a median increase of 7% (sample range 0-29%). The present study highlights some of the technical difficulties encountered when working with fresh tumour material ex vivo. We conclude that screening of patients for their suitability to enter clinical trials incorporating MDR modulating agents is technically demanding, but feasible.
引用
收藏
页码:69 / 74
页数:6
相关论文
共 50 条
  • [21] Whole solid tumor volume histogram parameters for predicting the recurrence in patients with epithelial ovarian carcinoma: a feasibility study on quantitative DCE-MRI
    Li, Hai Ming
    Tang, Wei
    Feng, Feng
    Zhao, Shu Hui
    Gu, Wei Yong
    Zhang, Guo Fu
    Qiang, Jin Wei
    ACTA RADIOLOGICA, 2020, 61 (09) : 1266 - 1276
  • [22] Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: A phase II study
    Gordinier, ME
    Kudelka, AP
    Kavanagh, JJ
    Wharton, JT
    Freedman, RS
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2002, 12 (06) : 710 - 714
  • [23] The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: A retrospective cohort study
    So, Kyeong A.
    Hong, Jin Hwa
    Jin, Hye Mi
    Kim, Jae Won
    Song, Jae Yun
    Lee, Jae Kwan
    Lee, Nak Woo
    GYNECOLOGIC ONCOLOGY, 2014, 132 (03) : 551 - 555
  • [24] Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study
    Myong Cheol Lim
    Young-Joo Won
    Jiwon Lim
    Tahereh Salehi
    Chong Woo Yoo
    Robert E. Bristow
    BMC Cancer, 18
  • [25] Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study
    Lim, Myong Cheol
    Won, Young-Joo
    Lim, Jiwon
    Salehi, Tahereh
    Yoo, Chong Woo
    Bristow, Robert E.
    BMC CANCER, 2018, 18
  • [26] Incidence of and risk factors for postoperative ileus in women undergoing primary staging and debulking for epithelial ovarian carcinoma
    Bakkum-Gamez, Jamie N.
    Langstraat, Carrie L.
    Martin, Janice R.
    Lemens, Maureen A.
    Weaver, Amy L.
    Allensworth, Sumer
    Dowdy, Sean C.
    Cliby, William A.
    Gostout, Bobbie S.
    Podratz, Karl C.
    GYNECOLOGIC ONCOLOGY, 2012, 125 (03) : 614 - 620
  • [27] Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma
    Rauh-Hain, J. Alejandro
    Nitschmann, Caroline C.
    Worley, Micheal J., Jr.
    Bradford, Leslie S.
    Berkowitz, Ross S.
    Schorge, John O.
    Campos, Susana M.
    del Carmen, Marcela G.
    Horowitz, Neil S.
    GYNECOLOGIC ONCOLOGY, 2013, 129 (01) : 63 - 68
  • [28] Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study
    Look, KY
    Bookman, MA
    Schol, J
    Herzog, TJ
    Rocereto, T
    Vinters, J
    GYNECOLOGIC ONCOLOGY, 2004, 92 (01) : 93 - 100
  • [29] Feasibility and outcome of primary laparoscopic cytoreductive surgery for advanced epithelial ovarian cancer: a comparison to laparotomic surgery in retrospective cohorts
    Liang, Huamao
    Guo, Hongyan
    Zhang, Chunyu
    Zhu, Fuli
    Wu, Yu
    Zhang, Kun
    Li, Hua
    Han, Jinsong
    ONCOTARGET, 2017, 8 (68) : 113239 - 113247
  • [30] Surgery at Primary Versus Relapsed Epithelial Ovarian Cancer: A Study on Aspects of Anaesthesiological Management
    Feldheiser, Aarne
    Bar Yosef, Anne
    Braicu, Elena-Ioana
    Bonomo, Tommaso
    Kaufner, Lutz
    Spies, Claudia
    Sehouli, Jalid
    Fotopoulou, Christina
    Pietzner, Klaus
    ANTICANCER RESEARCH, 2015, 35 (03) : 1591 - 1601